A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System Lymphoma
Authors:
- Yu Tung LoYLYu Tung Lo
- Vivian Yujing LimVLVivian Yujing Lim
- Melissa NgMNMelissa Ng
- Ya Hwee TanYTYa Hwee Tan
- Jianbang ChiangJCJianbang Chiang
- Esther Wei Yin ChangECEsther Wei Yin Chang
- Jason Yongsheng ChanJCJason Yongsheng Chan
- Eileen Yi Ling PoonEPEileen Yi Ling Poon
- Nagavalli SomasundaramNSNagavalli Somasundaram
- Mohamad Farid Bin Harunal RashidMRMohamad Farid Bin Harunal Rashid
- Miriam TaoMTMiriam Tao
- Soon Thye LimSLSoon Thye Lim
Open Access
Abstract
Background: Ratios of differential blood counts (hematological indices, HIs) had been identified as prognostic variables in various cancers. In primary central nervous system lymphomas (PCNSLs), higher baseline neutrophil-lymphocyte ratio (NLR) in particular was found to portend a worse overall survival. However, it was often observed that differential counts shift drastically following steroid administration. Moreover, steroids are an important part of the arsenal against PCNSL due to its potent lymphotoxic effects. We showed that the effect of steroids on differential blood cell counts and HIs could be an early biomarker for subsequent progression-free (PFS) and overall survival (OS). Methods: This study retrospectively identified all adult patients who received a brain biopsy from 2008 to 2019 and had histologically confirmed PCNSL, and included only those who received chemoimmunotherapy, with documented use of corticosteroids prior to treatment induction. Different blood cell counts and HIs were calculated at three time-points: baseline (pre steroid), pre chemoimmunotherapy (post steroid) and post chemoimmunotherapy. Tumor progression and survival data were collected and analyzed through Kaplan–Meier estimates and Cox regression. We then utilized selected variables found to be significant on Kaplan–Meier analysis to generate a decision-tree prognostic model, the NNI-NCCS score. Results: A total of 75 patients who received chemoimmunotherapy were included in the final analysis. For NLR, OS was longer with higher pre-chemoimmunotherapy (post-steroid) NLR (dichotomized at NLR ≥ 4.0, HR 0.42, 95% CI: 0.21–0.83, p = 0.01) only. For platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR), OS was better for lower post-chemoimmunotherapy PLR (dichotomized at PLR ≥ 241, HR 2.27, 95% CI: 1.00 to 5.18, p = 0.05) and lower pre-chemoimmunotherapy (post-steroid) LMR (dichotomized at LMR ≥25.7, HR 2.17, 95% CI: 1.10 to 4.31, p = 0.03), respectively, only. The decision-tree model using age ≤70, post-steroid NLR >4.0, and pre-steroid (baseline) NLR <2.5 and the division of patients into three risk profiles—low, medium, and high—achieved good accuracy (area-under-curve of 0.78), with good calibration (Brier score: 0.16) for predicting 2-year overall survival. Conclusion: We found that post-steroid NLR, when considered together with baseline NLR, has prognostic value, and incorporation into a prognostic model allowed for accurate and well-calibrated stratification into three risk groups.Keywords
Funding Information
- Nurturing Clinician Scientists Scheme (SingHealth) (1)
This publication has 28 references indexed in Scilit:
- Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS LymphomaJournal of Clinical Oncology, 2007
- Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic ModelJournal of Clinical Oncology, 2006
- Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevanceCell Death & Differentiation, 2004
- Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Glucocorticoid-Induced GranulocytosisCirculation, 1998
- An instructive false diagnosis: Steroid-induced complete remission of a CNS tumor ? probably lymphomaNeurosurgical Review, 1998
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Prolonged Corticosteroid-lnduced Remission in Primary Central Nervous System Lymphoma: Report of a Case and Review of the LiteratureEuropean Neurology, 1996
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Primary cerebral lymphoma: the “ghost tumor”Journal of Neurosurgery, 1984